MORF-627

MORF-627 is an orally bioavailable, small molecule integrin inhibitor developed by Morphic Therapeutic as a development candidate for fibrotic diseases such as idiopathic pulmonary fibrosis and other αvβ6‑mediated fibrotic indications. It is a highly potent and selective antagonist of integrin αvβ6 that stabilizes the bent‑closed (inactive) conformation of the receptor, thereby blocking αvβ6‑mediated activation of transforming growth factor beta (TGFβ) and downstream profibrotic signaling. Preclinical studies demonstrated good oral pharmacokinetics and efficacy in lung fibrosis models, but a 28‑day oral toxicity study in cynomolgus monkeys revealed urothelial proliferative lesions and urothelial carcinoma in the urinary bladder at high doses, leading to discontinuation of further development; MORF‑627 is now primarily used as a tool compound to study integrin αvβ6 biology.[1][3][4][2][7][9]